BioCatalystWatch
INVAWorkspace / INVA / OverviewCompany library
Innoviva, Inc. logo

Innoviva, Inc.

Innoviva, Inc. (INVA)

Website

Featured programme · XACDURO (sulbactam/durlobactam)

Price
Market cap
Next catalyst—
Cash

Chart & Events

Candle interval

Core Clinical

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Other pipelines

Partner / License out

Muscarinic receptor × β2-adrenergic receptor

Approved

PreINDP1P2P3FilingApproved

Approved / commercial

Muscarinic receptor × β2-adrenergic receptor

Approved

PreINDP1P2P3FilingApproved

Muscarinic receptor × β2-adrenergic receptor

Approved

PreINDP1P2P3FilingApproved

Bacterial type II topoisomerase

PreINDP1P2P3FilingApproved

β2-adrenergic receptor

Approved

PreINDP1P2P3FilingApproved

β2-adrenergic receptor

Approved

PreINDP1P2P3FilingApproved

History / paused

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

INVA SEC archive